Incoercible hematuria due to prolonged treatment with cyclophosphamide
Scetbon, V.
Journal d'Urologie et de Nephrologie 79(12 Part 2): 472-476
1973
ISSN/ISBN: 0021-8200 PMID: 4804422 Document Number: 70075
Document emailed within 1 workday
Related Documents
Guillou, M.L.; Merland, J.J.; Lepage, T.; Giraud, B.; Bories, J.; Küss, R. 1975: Control of incoercible vesical hematuria by selective vesical embolization. 7 cases of radium induced cystitis and of recurrent tumors La Nouvelle Presse Medicale 23: 1703-1708Uysal, M.; Ozdogan, M.; Kargi, A.; Gunduz, S.; Sezgin Goksu, S.; Murat Tatli, A.; Arslan, D.; Mutlu, H.; Senol Coskun, H.; Bozcuk, H. 2014: Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 19(4): 980-984
Novikov, T.K.; Kondrat'eva, I.A.; Fontalin, L.N.; Pevnitskiĭ, L.A. 1976: Factors determining prolonged chimerism of lymphoid tissue in mice treated with cyclophosphamide Biulleten' Eksperimental'noi Biologii i Meditsiny 81(2): 194-197
Obroniecka, I. 1998: Values of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part I. Establishing individual norms for glomerular hematuria Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 5(29): 277-279
Hainsworth, J.D.; Wolff, S.N.; Stein, R.S.; Greer, J.P.; Cousar, J.B.; Greco, F.A. 1986: Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis Cancer Treatment Reports 70(8): 953-958
Bezwoda, W.R.; Rastogi, R.B. 1994: A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up Seminars in Hematology 31(2 Suppl 3: 3
Harada, M.; Omoto, K.; Kimura, G.; Nomoto, K. 1995: Priming with donor spleen cells and activated B cells can induce prolonged survival of class I-disparate skin allografts in cyclophosphamide-treated mice Transplantation 60(5): 517-519
Liskiewicz, Z.; Maj, S.; Ziemski, J.M. 1971: Renal complications during treatment of hematuria in hemophilia a with epsilon-aminocaproic acid (EACA) Polski Tygodnik Lekarski 26(4): 145-147
Kesseler, A.; Aladenise, J.; Boivin, M.J.; Greninger, G. 1977: Macroscopic hematuria during treatment with phenylbutazone derivatives. Positive lymphocyte transformation test for these drugs. two cases in children Annales de Pediatrie 24(10): 703-707
Trouillas, P.; Neuschwander, P.; Nighoghossian, N.; Adeleine, P.; Tremisi, P. 1989: Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years Revue Neurologique (Paris) 145(5): 369-377
Adam, Z.; Szturz, P.; Křen, L.; Krejčí, M.; Pour, L.; Svoboda, T.; Hanke, I.; Penka, I.; Koukalová, R.; Rehák, Z.; Cervinková, I.; Storková, T.; Král, Z.; Mayer, J. 2013: PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview Vnitrni Lekarstvi 59(4): 301-312
West, R.J.; Zweig, S.F. 1997: Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide European Journal of Gynaecological Oncology 18(5): 343-348
Dorets'kyĭ, V.V. 1991: The cyclophosphamide treatment of glomerulonephritis patients Vrachebnoe Delo 2: 51-53
Sakalová, A.; Hrubisko, M. 1975: Cyclophosphamide in the treatment of immune hemocytopenias Folia Haematologica 102(5): 559-564
Jardine, I.; Fenselau, C.; Appler, M.; Kan, M.N.; Brundrett, R.B.; Colvin, M. 1978: Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy Cancer Research 38(2): 408-415
Zephir, H.; De-Seze, J.; Senechal, O.; Stojkovic, T.; Ferriby, D.; Delisse, B.; Dubus, B.; Verier, A.; Hautecoeur, P.; Vermersch, P. 2002: Treatment of progressive multiple sclerosis with cyclophosphamide Revue Neurologique (Paris) 158(1): 65-69
Rosenbaum, J.T. 1994: Treatment of severe refractory uveitis with intravenous cyclophosphamide Journal of Rheumatology 21(1): 123-125
De Vita, S.; Neri, R.; Bombardieri, S. 1991: Cyclophosphamide pulses in the treatment of rheumatic diseases: an update Clinical and Experimental Rheumatology 9(2): 179-193
Demetriades, P.; Wesiroglou, G.; Mitseas, C.; Kontomerkos, A. 1973: Cyclophosphamide in the treatment of ankylosing spondylitis, a study on 66 cases Zeitschrift für Allgemeinmedizin 49(25): 1182-1186
Kovacević, Z.; Mitrović, D.; Tomić, I.; Jovanović, D.; Skatarić, V.; Dimitrijević, J.; Rabrenović, V.; Trifunović, G. 1999: Pulsed doses of cyclophosphamide in the treatment of Wegener's granulomatosis Vojnosanitetski Pregled 56(1): 31-37